Bcr-Abl Tyrosine Kinase Inhibitors:阻害薬のグローバル市場2015(薬開発、治験動向)

◆英語タイトル:Bcr-Abl Tyrosine Kinase Inhibitors -Pipeline Insights, 2015
◆発行会社/調査会社:DelveInsight
◆商品コード:DIMRMOA5133
◆発行日:2015年版(※最新版はお問い合わせください)
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:25以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Bcr-Abl Tyrosine Kinase Inhibitors:阻害薬のグローバル市場2015(薬開発、治験動向)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DelveInsight’s,“Bcr-Abl Tyrosine Kinase Inhibitors-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Bcr-Abl Tyrosine Kinase Inhibitors. This report provides information on the therapeutic development based on the Bcr-Abl Tyrosine Kinase Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

[Data Sources]

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action.


• The report provides a snapshot of the global therapeutic landscape of Bcr-Abl Tyrosine Kinase Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Bcr-Abl Tyrosine Kinase Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Bcr-Abl Tyrosine Kinase Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

*** レポート目次(コンテンツ)***

• Bcr-Abl Tyrosine Kinase Inhibitors Overview
• Bcr-Abl Tyrosine Kinase Inhibitors Disease Associated
• Bcr-Abl Tyrosine Kinase Inhibitors Pipeline Therapeutics
• Bcr-Abl Tyrosine Kinase Inhibitors Therapeutics under Development by Companies
• Bcr-Abl Tyrosine Kinase Inhibitors Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Bcr-Abl Tyrosine Kinase Inhibitors Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Bcr-Abl Tyrosine Kinase Inhibitors Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Bcr-Abl Tyrosine Kinase Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Bcr-Abl Tyrosine Kinase Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Bcr-Abl Tyrosine Kinase Inhibitors – Discontinued Products
• Bcr-Abl Tyrosine Kinase Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for Bcr-Abl Tyrosine Kinase Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

• Number of Products under Development for Bcr-Abl Tyrosine Kinase Inhibitors by Therapy Area, 2015
• Number of Products under Development for Bcr-Abl Tyrosine Kinase Inhibitors, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Monotherapy Products
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Combination Products
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Route of Administration
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Stage and Route of Administration
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Molecule Type
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Stage and Molecule Type
• Bcr-Abl Tyrosine Kinase Inhibitors Therapeutics – Discontinued Products
• Bcr-Abl Tyrosine Kinase Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2015

• Number of Products under Development for Bcr-Abl Tyrosine Kinase Inhibitors by Therapy Area, 2015
• Number of Products under Development for Bcr-Abl Tyrosine Kinase Inhibitors, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Monotherapy Products
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Combination Products
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Route of Administration
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Stage and Route of Administration
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Molecule Type
• Bcr-Abl Tyrosine Kinase Inhibitors Assessment by Stage and Molecule Type

*** レポートのキーワード ***

薬剤、医薬品、製薬企業、試験、作用機序(MOA)、パイプライン、開発

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DIMRMOA5133 )"Bcr-Abl Tyrosine Kinase Inhibitors:阻害薬のグローバル市場2015(薬開発、治験動向)" (英文:Bcr-Abl Tyrosine Kinase Inhibitors -Pipeline Insights, 2015)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。